NCT04513717
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- NCT04513717 ↗
- Active, not recruiting
- NRG Oncology
- Standard
We haven't built an HCP commentary report on NCT04513717 (apalutamide, bicalutamide and 8 more in Prostate Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04513717 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 | |
| Podcasts | 7 | |
| YouTube | 4 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
- Arms
- Arm I (de-intensification study) · Active comparator
- Arm II (de-intensification study) · Experimental
- Arm III (intensification study) · Active comparator
- Arm IV (intensification study) · Experimental
- Enrollment
- 2,753
- Primary outcomes
- Metastasis-free survival (MFS)
- Sexual quality of life (De-intensification study)
- Hormonal quality of life (De-intensification study)
- Fatigue (Intensification study)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Jan 21, 2021
- Primary completion
- Dec 31, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT04513717 · updated Aug 17, 2026